649 POSTER Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. results of a two-cohort multicenter phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80945-0 ◽

2005 ◽

Vol 3 (2) ◽

pp. 184 ◽

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Single Agent ◽

Line Treatment ◽

Multicenter Phase

Download Full-text

Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e14002 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14002-e14002 ◽

Author(s):

M. Ychou ◽

O. Bouche ◽

S. Thézenas ◽

E. Francois ◽

A. Adenis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Multicenter Phase

Download Full-text

1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

European Journal of Cancer ◽

10.1016/s0959-8049(16)30565-2 ◽

2015 ◽

Vol 51 ◽

pp. S194-S195 ◽

Author(s):

D. Kienle ◽

R. Winterhalder ◽

D. Koeberle ◽

D. Horber ◽

M. Kueng ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial

Cancer Medicine ◽

10.1002/cam4.3618 ◽

2020 ◽

Author(s):

Eiji Oki ◽

Akitaka Makiyama ◽

Yuji Miyamoto ◽

Masahiko Kotaka ◽

Hirofumi Kawanaka ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

Journal of Geriatric Oncology ◽

10.1016/j.jgo.2018.11.011 ◽

2019 ◽

Vol 10 (2) ◽

pp. 304-310 ◽

Author(s):

Dirk L. Kienle ◽

Daniel Dietrich ◽

Karin Ribi ◽

Andreas Wicki ◽

Luca Quagliata ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Older Patients ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1016/s0923-7534(21)00330-6 ◽

2016 ◽

Vol 27 ◽

pp. ix54

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

Download Full-text

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)

Annals of Oncology ◽

10.1093/annonc/mdx393.055 ◽

2017 ◽

Vol 28 ◽

pp. v179

Author(s):

E. Samalin ◽

H. Senellart ◽

S. Thezenas ◽

S. Jacquot ◽

S. Ellis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii

Download Full-text

6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71736-1 ◽

2011 ◽

Vol 47 ◽

pp. S418

Author(s):

E. Samalin ◽

O. Bouche ◽

S. Thezenas ◽

E. Frangois ◽

A. Adenis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Multicentre Phase

Download Full-text

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text